Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia

References

• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia - an overview. JAMA Psychiatry. 2020;77(2):201–210. doi:10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• Kahn R, Sommer I, Murray R, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. doi:10.1038/nrdp.2015.67
   PubMed Web of Science ®Google Scholar
• Carrà G, Crocamo C, Angermeyer M, Brugha T, Toumi M, Bebbington P. Positive and negative symptoms in schizophrenia: a longitudinal analysis using latent variable structural equation modelling. Schizophr Res. 2019;204:58–64. doi:10.1016/j.schres.2018.08.018
   PubMed Web of Science ®Google Scholar
• Jongsma HE, Turner C, Kirkbride JB, Jones PB. International incidence of psychotic disorders, 2002–17: a systematic review and meta-analysis. Lancet Public Health. 2019;4(5):e229–e244. doi:10.1016/S2468-2667(19)30056-8
   PubMed Web of Science ®Google Scholar
• GBD. 2019 mental disorders collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Psychiatry. 2022;9(2):137–150. doi:10.1016/S2215-0366(21)00395-3
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Moeller HJ, Kasper S, et al. The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr. 2020;29:1–25. doi:10.1017/S1092852920001546
   Web of Science ®Google Scholar
• Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269–284. doi:10.1017/S1461145710001380
   PubMed Web of Science ®Google Scholar
• Correll CU, Kane JM. Ranking antipsychotics for efficacy and safety in schizophrenia. JAMA Psychiatry. 2020;77:225–226. doi:10.1001/jamapsychiatry.2019.3377
   PubMed Web of Science ®Google Scholar
• Bartoli F, Carrà G, Crocamo C, Carretta D, Clerici M. Bipolar disorder, schizophrenia, and metabolic syndrome. Am J Psychiatry. 2013;170(8):927–928. doi:10.1176/appi.ajp.2013.13040447
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–242. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Bartoli F, Crocamo C, Clerici M, Carrà G. Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neuropsychophar. 2015;25(10):1767–1774. doi:10.1016/j.euroneuro.2015.06.011
   PubMed Web of Science ®Google Scholar
• Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2020;15(168):107634. doi:10.1016/j.neuropharm.2019.05.011
   Web of Science ®Google Scholar
• Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW. Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. J Clin Psychiatry. 2018;79(4):17m11874. doi:10.4088/JCP.17m11874
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. doi:10.1177/2045125312474019
   PubMedGoogle Scholar
• Kane JM, Correll CU. The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry. 2016;73(3):187–188. doi:10.1001/jamapsychiatry.2015.2966
   PubMed Web of Science ®Google Scholar
• Kokurcan A. Comparison of clinical characteristics between the patients with schizophrenia on clozapine treatment with those taking combination of long-acting injectable and oral antipsychotics. Noro Psikiyatr Ars. 2019;56(3):219–223. doi:10.29399/npa.23548
   PubMedGoogle Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44:603–619. doi:10.1093/schbul/sbx090
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Mazzi MA, Terlizzi S, et al. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One. 2018;13(8):e0201371. doi:10.1371/journal.pone.0201371
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):424–436. doi:10.1176/appi.ajp.2020.20071120
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C. doi:10.4088/JCP.IN18031AH1C
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74:957–965. doi:10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar
• Kokurcan A, Güriz SO, Karadağ H, Erdi F, Örsel S. Treatment strategies in management of schizophrenia patients with persistent symptoms in daily practice: a retrospective study. Int J Psychiatry Clin Pract. 2021;25(3):238–244. doi:10.1080/13651501.2021.1879157
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686–693. doi:10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8(1):5. doi:10.1038/s41537-021-00192-x
   Web of Science ®Google Scholar
• Pietrini F, Albert U, Ballerini A, et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1045–1060. doi:10.2147/NDT.S199048
   PubMed Web of Science ®Google Scholar
• Paton C, Okocha CI, Patel MX. Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? Ther Adv Psychopharmacol. 2022;12:20451253211072347. doi:10.1177/20451253211072347
   Web of Science ®Google Scholar
• Barbui C, Bertolini F, Bartoli F, et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR network depot study. Ther Adv Psychopharmacol. 2020;10:2045125320978102. doi:10.1177/2045125320978102
   Web of Science ®Google Scholar
• Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. doi:10.1007/s40263-016-0350-7
   PubMed Web of Science ®Google Scholar
• Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340. doi:10.1186/1471-244X-13-340
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed October 3, 2022.
   Google Scholar
• European Medicines Agency. Public Data from Article 57 Database. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/data-medicines-iso-idmp-standards/public-data-article-57-database. Accessed October 3, 2022.
   Google Scholar
• Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. New Jersey: Wiley-Blackwell; 2021.
   Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi:10.1002/wps.20994
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295–307. doi:10.1002/wps.20972
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836. doi:10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar
• Højlund M, Kemp AF, Haddad PM, Neill JC, Correll CU. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry. 2021;8(6):471–486. doi:10.1016/S2215-0366(21)00078-X
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469–481. doi:10.1007/s40263-021-00815-y
   PubMed Web of Science ®Google Scholar
• Saucedo Uribe E, Carranza Navarro F, Guerrero Medrano AF, et al. Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: a systematic review and meta-analysis. J Psychiatr Res. 2020;129:222–233. doi:10.1016/j.jpsychires.2020.06.013
   PubMed Web of Science ®Google Scholar
• Olagunju AT, Clark SR, Baune BT. Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome. Aust N Z J Psychiatry. 2019;53(6):509–527. doi:10.1177/0004867419837358
   PubMed Web of Science ®Google Scholar
• Pae CU, Wang SM, Han C, et al. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017;32(5):235–248. doi:10.1097/YIC.0000000000000177
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull. 2016;42(6):1438–1445. doi:10.1093/schbul/sbw043
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10–21. doi:10.1016/j.schres.2016.11.010
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. doi:10.1176/appi.ajp.162.3.441
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. doi:10.3109/15622975.2012.739708
   PubMed Web of Science ®Google Scholar
• Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S7–S12. doi:10.1192/bjp.195.52.s7
   PubMedGoogle Scholar
• Taylor D. Establishing a dose–response relationship for haloperidol decanoate. Psychiatr Bull. 2005;29(3):104–107. doi:10.1192/pb.29.3.104
   Google Scholar
• Ehret MJ, Davis E, Luttrell SE, Clark C. Aripiprazole lauroxil nanoCrystal® dispersion technology (Aristada Initio®). Clin Schizophr Relat Psychoses. 2018;12(2):92–96. doi:10.3371/CSRP.EHDA071918
   PubMedGoogle Scholar
• Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289–295. doi:10.1097/JCP.0000000000000691
   PubMed Web of Science ®Google Scholar
• Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159(2–3):404–410. doi:10.1016/j.schres.2014.09.021
   PubMed Web of Science ®Google Scholar
• Luedecke D, Schöttle D, Karow A, Lambert M, Naber D. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29(1):41–46. doi:10.1007/s40263-014-0216-9
   PubMed Web of Science ®Google Scholar
• Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Drugs. 2012;72(8):1137–1160. doi:10.2165/11208640-000000000-00000
   PubMed Web of Science ®Google Scholar
• Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767–783. doi:10.1586/14737175.2013.811984
   PubMed Web of Science ®Google Scholar
• Jann MW, Penzak SR. Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs. 2018;32(3):241–257. doi:10.1007/s40263-018-0508-6
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–117. doi:10.1016/j.euroneuro.2004.07.003
   PubMed Web of Science ®Google Scholar
• Andorn A, Graham J, Csernansky J, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 Program. J Clin Psychopharmacol. 2019;39(5):428–433. doi:10.1097/JCP.0000000000001076
   PubMed Web of Science ®Google Scholar
• Carrà G, Crocamo C, Bartoli F, et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum Psychopharmacol. 2016;31(4):313–318. doi:10.1002/hup.2540
   PubMed Web of Science ®Google Scholar
• Barbui C, Bighelli I, Carrà G, et al. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS One. 2016;11(2):e0148212. doi:10.1371/journal.pone.0148212
   PubMed Web of Science ®Google Scholar
• Aguglia A, Fusar-Poli L, Natale A, et al. Factors associated with medication adherence to long-acting injectable antipsychotics: results from the STAR Network depot study. Pharmacopsychiatry. 2022;55:281–289. doi:10.1055/a-1804-6211
   PubMed Web of Science ®Google Scholar
• Bartoli F, Cavaleri D, Callovini T, et al. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: findings from the STAR network depot study. Psychiatry Res. 2022;309:114405. doi:10.1016/j.psychres.2022.114405
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–S41. doi:10.1016/j.jclinepi.2013.01.012
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23.
   PubMed Web of Science ®Google Scholar